Clinical Trial Update: A Study of Ramucirumab or Icrucumab in Colorectal Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update evaluating ramucirumab or icrucumab in colorectal cancer has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colon Cancer
• Rectal Cancer

Drugs mentioned

• Icrucumab (icrucumab)
• Ramucirumab (ramucirumab)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Colon Cancer, Rectal Cancer | Phase 2 | Status: COMPLETED | Results posted: 2019-08-06